Navigation Links
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Date:5/21/2013

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 – 4:30 PM.  The presentation will describe the results of a first-in-human study of MacroGenics' next-generation anti-HER2 monoclonal antibody, margetuximab, which is being developed to treat HER2-expressing tumors.  

MacroGenics has optimized the Fc region of margetuximab to increase cancer cell killing via Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).  Margetuximab also has shown improved control of tumor growth in human tumor xenograft models in mice as compared to that of anti-HER2 antibodies with a wild type Fc region.  A development goal for margetuximab is to enable the treatment of a broader population of patients than those eligible for treatment with current HER2-targeted therapies.

MacroGenics also announced that the first patient has received study drug in a Phase 2 clinical study evaluating margetuximab in patients with metastatic breast cancer.  This study is designed to evaluate the activity of margetuximab in up to 41 patients with metastatic breast cancer whose tumors express a moderate level of the oncoprotein, HER2, represented by a 2+ score by immunohistochemistry.  These tumors must also lack evidence of HER2 gene amplification as determined by FISH testing.  The trial is being conducted at six sites across the United States.  For more information on the clinical trial, please see www.clinicaltrials.gov.

"To date, the results of our Phase 1 s
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
2. Revolutionary Science Announces New Automatic and Manual Colony Counting Products
3. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
4. SoundConnect Announces Microsoft Lync Release in Canada
5. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
6. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
7. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
8. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
9. DNA Genotek Inc. Announces Spit for Africa Program
10. Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
11. Discovery Labs Announces Completion of $14.25 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 ... leader in Personalized Medicine, is excited to announce ... Genetic Testing to Optimize the Management of Pain”. ... available at Medscape.com for the next year. The ... professionals how to recognize inadequate pain treatments, integrate ...
(Date:3/4/2015)... San Jose, California (PRWEB) March 04, 2015 ... Chain Reaction (PCR) represents one of the fastest growing ... among cell biologists in subcellular visualization is driving growth ... The need for deeper understanding of gene expressions will ... reagents market. Expanding applications in fields ranging from pharma, ...
(Date:3/3/2015)... DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... the quarter and seventh-month period ended December 31, 2014. ... its fiscal year end from May 31 to December ... we are reporting today are for the quarter and ...
(Date:3/3/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... control projects in North America , the ... "Bidding activity in 2015 continues to be robust" said ... volume year for bidding in 2014, we are pleased to see ... reflect the organization,s renewed focus on select market segments where we ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... the atomic forces that cause friction, thanks to a ... Pennsylvania, the University of Houston and the U.S. Department ... by Robert Carpick of the University of Pennsylvania, found ... that had been coated with different isotopes of hydrogen ...
... CARMIEL, Israel, Nov. 2 Protalix,BioTherapeutics, Inc. (Amex: ... Aviezer,Ph.D., its President and Chief Executive Officer, will ... Conference. Dr. Aviezer,s presentation,will take place at 3:00 ... Hotel in New York City. Dr. Aviezer,s ...
... Confirmed, REINACH and BASEL, Switzerland, November 2 ... on its late-stage,investigational antibiotic iclaprim at the 9th ... VKliPha) which takes place,1-3 November in Kiel, Germany. ... substantial volume of data on iclaprim that is ...
Cached Biology Technology:Heavier hydrogen on the atomic scale reduces friction 2Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 2Arpida Presents Data on Iclaprim at Scientific Congress in Germany 3Arpida Presents Data on Iclaprim at Scientific Congress in Germany 4
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a ... discovery, announced the launch of a TR-FRET (time ... company,s Transcreener UDP Assay, a high throughput screening ... new assay will allow for sensitive detection of ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... that protects metals against corrosion in seawater has ... Sheffield Hallam University. At the Society for General ... Jeanette Gittens and colleagues described how they had ... coating which then protected an aluminium alloy from ...
... Institutes of Health (NIH) researchers have identified a gene that ... cancer. The finding is reported today in the journal ... of a group of enzymes implicated in skin cancer and ... found that one-quarter of human melanoma tumors had changes, or ...
... insight into mechanisms that allow invasive tumor cells to move, ... new understanding about how to stop cancer from spreading. A ... is the process that most often leads to death from ... Nature Cell Biology , researchers say that a molecule ...
Cached Biology News:Skin cancer study uncovers new tumor suppressor gene 2Skin cancer study uncovers new tumor suppressor gene 3Mayo Clinic researchers discover and manipulate molecular interplay that moves cancer cells 2
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... TOPO Cloning is the ... for cloning PCR products. ... Zero Blunt TOPO vectors ... activated with topoisomerase I. ...
Applications: ISH...
... Immunogen: Recombinant human IDO (Indoleamine-pyrrol ... the ~44 kDa human IDO ... control: IFN-Gamma-stimmulated Human peripheral blood ... reactivity with mouse and rat ...
Biology Products: